RCRI — Perioperative Cardiac Risk Guide
The Revised Cardiac Risk Index (RCRI), also known as the Lee Index, was published by Thomas Lee and colleagues in 1999 (Circulation) based on a prospective cohort study of 4,315 patients undergoing elective non-cardiac surgery at a single academic medical centre. It identified six independent predictors of major adverse cardiac events (MACE) — defined as myocardial infarction, pulmonary oedema, ventricular fibrillation or primary cardiac arrest, and complete heart block. The RCRI has been externally validated in multiple populations worldwide and remains the most widely used preoperative cardiac risk stratification tool, endorsed by ACC/AHA 2014 guidelines for preoperative cardiac evaluation.
RCRI Score and MACE Risk
| RCRI Score | MACE Risk (Lee 1999) | MACE Risk (Revised estimates) | Risk Category |
|---|---|---|---|
| 0 | 0.4% | 3.9% | Very Low |
| 1 | 0.9% | 6.0% | Low |
| 2 | 6.6% | 10.1% | Moderate |
| ≥3 | 11% | 15% | High |
Note: Revised estimates from Duceppe et al. 2017 meta-analysis (JAMA Internal Medicine) are higher than Lee's original derivation cohort estimates, reflecting broader population validation.
The 6 RCRI Criteria Explained
- High-risk surgery: Intraperitoneal, intrathoracic, and suprainguinal vascular procedures carry the highest surgical risk. Low-risk surgeries (superficial procedures, endoscopy, cataract) are excluded from RCRI use
- Ischaemic heart disease: History of MI, positive exercise stress test, current chest pain thought to be ischaemic, use of nitrate therapy, or ECG with Q waves in any lead
- Congestive heart failure: History of HF, pulmonary oedema, paroxysmal nocturnal dyspnoea, bilateral rales on examination, or S3 gallop, or chest X-ray showing pulmonary vascular redistribution
- Cerebrovascular disease: History of ischaemic stroke, TIA, or carotid endarterectomy. Reflects generalised atherosclerotic burden and risk of perioperative haemodynamic vulnerability
- Insulin-dependent diabetes: Insulin therapy specifically — not oral hypoglycaemics alone. Insulin-dependent diabetes is a proxy for advanced disease and autonomic dysfunction
- Preoperative creatinine >2.0 mg/dL: Reflects significant chronic kidney disease (approximately CKD Stage 4 or worse). Renal insufficiency impairs perioperative haemodynamic reserve and increases cardiac stress
ACC/AHA 2014 Preoperative Cardiac Evaluation Steps
- Step 1 — Emergency surgery? Proceed to surgery with perioperative surveillance. No time for evaluation
- Step 2 — Active cardiac conditions? Unstable coronary syndrome, decompensated HF, significant arrhythmias, severe valvular disease → postpone surgery, evaluate and treat first
- Step 3 — Low-risk surgery? Risk <1% even without testing → proceed
- Step 4 — Good functional capacity (≥4 METs)? Can climb a flight of stairs, walk on level ground at 4 mph, or do light housework without symptoms → proceed without further testing
- Step 5 — Unknown/poor functional capacity with RCRI ≥3? Pharmacological stress testing may change management → consider non-invasive testing. If tests don't change management, proceed with surgery
Perioperative Beta-Blocker Management
ACC/AHA 2014 guidelines on perioperative beta-blockers: Continue beta-blockers in patients already taking them (Class I). Consider perioperative beta-blockers for patients with 3 or more RCRI risk factors — but do NOT start beta-blockers on the day of surgery. If initiating beta-blockers, start at least 2–7 days before surgery with dose titration to achieve HR 60–80 bpm. Avoid high-dose beta-blockers in beta-blocker-naive patients — the POISE trial showed they reduced MI but increased stroke and overall mortality at high doses.
Perioperative Statin Therapy
Statins have pleiotropic effects beyond LDL-lowering — anti-inflammatory, plaque-stabilising, and endothelial effects that may reduce perioperative cardiac events. ACC/AHA 2014 recommends: Continue statins in patients currently taking them. Initiating statins may be reasonable in patients undergoing vascular surgery with or without elevated cardiac biomarkers. For non-vascular surgery, statin initiation in high-risk patients may be considered but evidence is less robust.